Navigation Links
Conatus Pharmaceuticals Appoints Daniel Ripley As Head Of Corporate Development
Date:7/17/2012

SAN DIEGO, July 17, 2012 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the appointment of Daniel Ripley as Head of Corporate Development, effective immediately.  Mr. Ripley will lead licensing, partnering initiatives, intellectual property analysis and act as the internal coordinator of the emricasan commercialization strategy development.

"Dan brings experience in both in-licensing and out-licensing of commercial products as well as extensive experience in partnering early-to-late stage products", said Steven J. Mento, Ph.D., President and CEO. "His varied experience in drug development transactions will be particularly important as we move forward with the development of emricasan, our first-in-class caspase inhibitor, into Phase 3 clinical trials for acute liver failure and liver fibrosis, and the related coordination of its commercialization activities".

We also want to continue our strong track record of success with collaborative drug discovery partnerships with large pharmaceutical companies, expanding the development of emricasan for disease targets other than liver disease as well as monitoring our collaboration with Abbott Laboratories in cancer," continued Dr. Mento.  "In addition, we have a leadership position in intellectual property related to programmed cell death (apoptosis) including ongoing relationships with thought leaders in the field of apoptosis and in our targeted disease areas. We possess an extensive patent portfolio comprised of over 130 issued patents including patents covering composition of matter on validated drug targets and new chemical entities (NCEs) addressing those targets, as well as broad fields of use, drug-screening assays, diagnostics and antibodies.  Dan will be involved in seeking business opportunities in each of these areas".

For more than a decade, Mr. Ripley has been involved with emerging growth life science companies in the development and execution of strategic business transactions.  His experiences include M&A, technology licenses and alliance transactions with pharmaceutical companies.  Mr. Ripley was instrumental in business negotiations at Kalypsys, Inc. and Isis Pharmaceuticals where he closed over $350 million in transactions.

Mr. Ripley earned his M.B.A. with an emphasis in Finance and a B.S. in Microbiology both from San Diego State University.

Conatus Pharmaceuticals Inc. is a privately-held biopharmaceutical company engaged in the development of innovative human therapeutics in the areas of fibrotic disease and oncology. Conatus' lead drug candidate, emricasan (IDN-6556) is in development as a potential therapy for a variety of fibrotic diseases. Fibrotic diseases affect millions of people worldwide and can be caused by many different types of injuries. Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer.   Conatus acquired the Idun subsidiary from Pfizer in 2010.  For additional information, please visit www.conatuspharma.com.


'/>"/>
SOURCE Conatus Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... offer newly issued shares of common stock, $0.01 par value ... an underwritten public offering.  The final terms of the Offering ... of pricing, and there can be no assurance as to ... IRIDEX expects to use the net proceeds it will receive ...
(Date:12/8/2016)... -- Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices Market Outlook to 2022", provides ... Devices market. The report provides value, in millions ... prices (USD) within market segement - Glaucoma Drainage ... and distribution shares data for each of these ...
(Date:12/8/2016)... 2016  The global biosurgery market is expected to ... period of 2016 to 2021. The market is poised ... 18.21 billion in 2016. The market is primarily driven ... related injuries and spinal problems, increasing clearance of biosurgery ... blood loss management. In this report, the ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching ... innovative Unified Instance Manager architecture, meeting the needs of multichannel growth and ... the unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to announce that ... for Texas, they are expanding their presence in Dallas. One of the most exciting ... bring new jobs to the Dallas and Forth Worth market. STAT takes pride in ...
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare is ... Dr. Botelho advocates for the mass media launching of story movements to highlight ... to share their unfortunate experiences; such a movement can generate the network power ...
Breaking Medicine News(10 mins):